Wilson Wai-Shun Cheung is CFO & VP at SCICLONE PHARMACEUTICALS INC (SCLN). They have made 6 open-market trades across 2 companies since 2008, most recently 2017-10-13.
CIK 0000880771
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1K since 2008, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SCLN | SELL | 2017-06-12 | 2017-06-14 | $10.75 | $435K | +1.4% | +1.4% | +2.3% |
| SCLN | SELL | 2016-10-25 | 2016-10-27 | $10.00 | $1.5M | +0.5% | +12.6% | +17.0% |
| SCLN | SELL · 10b5-1 | 2016-10-17 | 2016-10-19 | $10.00 | $15K | -8.7% | +6.1% | +6.1% |
| SCLN | SELL | 2016-08-29 | 2016-08-29 | $10.35 | $19K | -3.1% | +1.9% | -1.5% |
| SCLN | SELL | 2016-08-16 | 2016-08-16 | $10.62 | $83K | -1.1% | -3.2% | -2.5% |
| SCLN | SELL | 2016-08-16 | 2016-08-16 | $10.62 | $166K | -1.1% | -3.2% | -2.5% |
| SCLN | SELL · 10b5-1 | 2015-11-10 | 2015-11-10 | $9.51 | $74K | -15.6% | -3.7% | -6.3% |
| SCLN | SELL · 10b5-1 | 2015-03-12 | 2015-03-16 | $9.07 | $71K | -15.6% | -3.7% | -3.7% |
| AXTI | BUY | 2008-11-10 | 2008-11-10 | $1.26 | $1K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-05-01 | 2008-05-02 | $5.11 | $85K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-04-28 | 2008-04-29 | $5.00 | $17K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-04-07 | 2008-04-08 | $5.00 | $50K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-03-27 | 2008-03-28 | $5.01 | $45K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-03-24 | 2008-03-26 | $5.00 | $5K | -2.0% | +6.5% | +6.5% |
| AXTI | SELL · 10b5-1 | 2008-03-06 | 2008-03-10 | $5.03 | $50K | -2.0% | +6.5% | +6.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.